Purine and pyrimidine metabolism and disorders

Reading File

Finding Sources

Searching PubMed

purine pyrimidine metabolism disorders

Reading File

Loading Image

Reading File

Finding Sources

I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer:

Purine and Pyrimidine Metabolism and Disorders

1. Overview and Functions of Nucleotides

Purines and pyrimidines are the nitrogen-containing bases that form the backbone of nucleotides and nucleic acids. Beyond DNA and RNA synthesis, nucleotides serve multiple roles:

Energy currency: ATP, GTP
Coenzymes: NAD+, FAD, Coenzyme A
Activated intermediates: UDP-glucose (glycogen synthesis), CDP-diacylglycerol (phospholipid synthesis)
Second messengers: cAMP, cGMP
Allosteric regulators of metabolic enzymes

Dietary nucleic acid contributes minimally to the nucleotide pool; pancreatic DNase and RNase digest ingested nucleic acids, but intestinal epithelial cells efficiently catabolize the products. Nucleotides must therefore be synthesized endogenously.

Basic Medical Biochemistry, 6e, p. 1404

2. Purine Metabolism

A. De Novo Synthesis

Purines are built atom by atom on a ribose 5-phosphate scaffold. The process is complex (11 steps), energy-expensive (6 ATP per purine), and starts with PRPP (5-phosphoribosyl-1-pyrophosphate).

Precursors contributing to the purine ring:

Origin of atoms in the purine ring - glycine provides C4, C5, N7; CO2 provides C6; aspartate provides N1; glutamine provides N3 and N9; N10-formyl-FH4 provides C2 and C8; ribose 5'-phosphate (RP) is the scaffold

FIGURE: Origin of atoms in the purine base. Glycine (C4, C5, N7), CO2 (C6), Aspartate-N (N1), Glutamine amide-N (N3, N9), N10-formyl-FH4 (C2, C8), and RP (ribose 5'-phosphate) are the building blocks.

Key steps:

PRPP synthetase converts ribose 5-phosphate + ATP → PRPP (rate-limiting, regulated by feedback inhibition from AMP/GMP)
The first committed step: glutamine → PRPP → 5-phosphoribosylamine (by amidophosphoribosyltransferase)
IMP (inosine monophosphate) is the first purine nucleotide synthesized
IMP → AMP (via adenylosuccinate, requiring GTP as energy)
IMP → GMP (via XMP, requiring ATP as energy)

This cross-regulation ensures balanced production of adenine and guanine nucleotides.

Regulation: Four key enzymes are allosterically regulated:

PRPP synthetase (inhibited by AMP, GMP, IMP)
Amidophosphoribosyltransferase (inhibited by AMP + GMP together)
IMP dehydrogenase
Adenylosuccinate synthetase
Basic Medical Biochemistry, 6e, p. 1404-1406; Harper's Illustrated Biochemistry, 32e

B. Purine Salvage Pathway

Since de novo synthesis is expensive, cells recycle free purine bases via salvage enzymes:

Enzyme	Reaction	Clinical relevance
HGPRT (hypoxanthine-guanine phosphoribosyltransferase)	Hypoxanthine/guanine + PRPP → IMP/GMP	Deficiency = Lesch-Nyhan syndrome
APRT (adenine phosphoribosyltransferase)	Adenine + PRPP → AMP	Deficiency = 2,8-dihydroxyadenine urolithiasis
Adenosine kinase	Adenosine + ATP → AMP + ADP	-
Adenosine deaminase (ADA)	Adenosine → Inosine	Deficiency = SCID
Purine nucleoside phosphorylase (PNP)	Inosine/guanosine → hypoxanthine/guanine	Deficiency = T-cell immunodeficiency

The purine nucleotide cycle in muscle converts aspartate carbons to fumarate (replenishing TCA cycle) and releases ammonia during exercise.

Basic Medical Biochemistry, 6e, p. 1405

C. Purine Catabolism

Purine nucleosides are degraded to their free bases and then catabolized to uric acid, the end product in humans (humans lack uricase, unlike most mammals which convert uric acid to allantoin, a more water-soluble product):

Purine catabolism pathway: Adenosine → (adenosine deaminase) → Inosine; Guanosine → Inosine/Guanosine → (purine nucleoside phosphorylase) → Hypoxanthine/Guanine → (xanthine oxidase) → Xanthine → (xanthine oxidase) → Uric acid

FIGURE: Formation of uric acid from purine nucleosides. Adenosine deaminase converts adenosine → inosine. Purine nucleoside phosphorylase cleaves inosine/guanosine to hypoxanthine/guanine. Xanthine oxidase converts hypoxanthine → xanthine → uric acid.

Key point: Uric acid has limited solubility. Elevated serum urate → crystal deposition in cooler peripheral tissues (e.g., first metatarsophalangeal joint) → gout.

3. Pyrimidine Metabolism

A. De Novo Synthesis

Unlike purines (assembled on ribose phosphate), pyrimidines are synthesized as the free base first, then attached to ribose phosphate.

Precursors: Aspartate + carbamoyl phosphate form all ring atoms.

Steps:

Carbamoyl phosphate synthetase II (CPSII) - cytoplasmic enzyme using glutamine (not ammonia); forms carbamoyl phosphate. This is the first committed, rate-limiting step, regulated by UTP (inhibitor) and PRPP (activator).
Carbamoyl phosphate + aspartate → carbamoyl aspartate → dihydroorotate → orotic acid
Orotic acid + PRPP → OMP (orotidine monophosphate) via orotate phosphoribosyltransferase
OMP → UMP via OMP decarboxylase (steps 3+4 are catalyzed by the bifunctional enzyme UMP synthase)
UMP → UDP → UTP → CTP (CTP synthetase adds amino group from glutamine)
UDP → dUDP → dUMP → dTMP (thymidylate synthase, requires N5,N10-methylene-FH4)

Key distinction from purine synthesis: Pyrimidine synthesis begins in the cytoplasm with carbamoyl phosphate made by CPSII; urea cycle uses mitochondrial carbamoyl phosphate from CPSI.

Basic Medical Biochemistry, 6e, p. 1406; Harper's Illustrated Biochemistry, 32e

B. Deoxyribonucleotide Synthesis

Ribonucleotide reductase reduces the 2'-OH of ribonucleotide diphosphates (ADP, GDP, CDP, UDP) to deoxyribonucleotides. Two allosteric sites:

Activity site (ATP activates, dATP inhibits overall activity)
Specificity site (determines which substrate is reduced)
Basic Medical Biochemistry, 6e, p. 1406-1407

C. Pyrimidine Catabolism

Unlike purines, pyrimidine catabolism produces water-soluble end products: CO2, NH3, β-alanine (from uracil/cytosine), and β-aminoisobutyrate (from thymine). This means excess pyrimidine catabolism rarely causes clinical disease.

Note: Increased β-aminoisobutyrate excretion occurs in leukemia, severe radiation exposure, and in many people of East Asian ancestry (benign polymorphism).

4. Disorders of Purine Metabolism

A. Gout and Hyperuricemia

The most common purine disorder. Uric acid crystals deposit in joints and soft tissues when serum urate exceeds solubility (~6.8 mg/dL).

Causes:

Primary (overproduction):
- PRPP synthetase overactivity (gain-of-function mutations: elevated Vmax, increased ribose 5-phosphate affinity, resistance to feedback inhibition)
- HGPRT partial deficiency (Kelley-Seegmiller syndrome)
Secondary overproduction: Cancer, psoriasis, myeloproliferative disorders (increased cell turnover)
Underexcretion (most common, ~90% of cases): Renal tubular handling abnormalities
Von Gierke Disease (glucose-6-phosphatase deficiency): Enhanced ribose 5-phosphate → PRPP → purine overproduction; associated lactic acidosis raises the renal threshold for urate

Treatment:

Acute attack: Colchicine (inhibits microtubule polymerization, blocks neutrophil migration), NSAIDs, corticosteroids
Chronic prevention: Allopurinol (xanthine oxidase inhibitor, structural analog of hypoxanthine; reduced to alloxanthine which is a tight-binding inhibitor), febuxostat (non-purine xanthine oxidase inhibitor), uricosurics (probenecid)

B. Lesch-Nyhan Syndrome

Defect: Complete absence of HGPRT (X-linked recessive, gene on Xq26-27)
Mechanism: HGPRT deficiency → cannot salvage hypoxanthine/guanine → intracellular PRPP accumulates → drives de novo purine overproduction → massive hyperuricemia
Clinical features:
- Hyperuricemia + uric acid nephrolithiasis
- Severe neurological: Self-mutilation (lip/finger biting - pathognomonic), choreoathetosis, dysarthria, hyperreflexia, hypertonia, cognitive impairment
- Behavioral: Compulsive self-injurious behavior
Genetics: Mutations include deletions, frameshift, base substitutions, aberrant mRNA splicing

Kelley-Seegmiller syndrome = partial HGPRT deficiency: hyperuricemia + gout without the neurological features.

Harper's, 32e, p. 355; Bradley and Daroff's Neurology, p. 1950

C. Adenosine Deaminase (ADA) Deficiency

Defect: ADA deficiency (autosomal recessive; most common cause of autosomal recessive SCID)
Mechanism: ADA normally converts adenosine → inosine and deoxyadenosine → deoxyinosine. Deficiency → accumulation of deoxyadenosine → accumulates as dATP in lymphocytes (lymphocytes lack efficient dephosphorylation) → dATP inhibits ribonucleotide reductase → depletes DNA precursors → lymphocyte apoptosis
Clinical: Severe Combined Immunodeficiency (SCID) - absent T cells AND B cells; infants die from infections without treatment
Treatment: Enzyme replacement therapy (PEG-ADA), gene therapy (historically important first successful gene therapy), bone marrow transplant

D. Purine Nucleoside Phosphorylase (PNP) Deficiency

Defect: PNP (autosomal recessive)
Mechanism: Accumulation of dGTP → inhibits ribonucleotide reductase → T cell depletion
Clinical: Severe T-cell deficiency with apparently normal B-cell function; autoimmune disorders; benign and opportunistic infections
Contrast with ADA deficiency: PNP affects mainly T cells; ADA affects both T and B cells

E. Xanthinuria (Xanthine Oxidase Deficiency)

Defect: Xanthine oxidase (genetic or severe liver damage)
Mechanism: Cannot convert hypoxanthine/xanthine → uric acid
Clinical: Hypouricemia + increased urinary excretion of hypoxanthine and xanthine; severe cases → xanthine urolithiasis (xanthine stones are less soluble than uric acid)

5. Disorders of Pyrimidine Metabolism

A. Orotic Aciduria

Type I - deficiency of both UMP synthase activities (orotate phosphoribosyltransferase + OMP decarboxylase):

Orotic acid accumulates and is excreted in urine
Megaloblastic anemia (cannot synthesize pyrimidines → no DNA synthesis in erythroid precursors)
Does NOT respond to folate or B12
Treatment: Uridine supplementation (bypasses the block; UMP is used downstream)

Type II - deficiency of OMP decarboxylase alone (rarer)

Secondary orotic aciduria: Occurs in urea cycle defects (especially OTC deficiency) where excess carbamoyl phosphate overflows to pyrimidine synthesis; also occurs with allopurinol/6-azauridine therapy.

B. Dihydropyrimidine Dehydrogenase (DPD) Deficiency

Defect: DPD (autosomal recessive)
Pathway role: DPD catalyzes the first step of pyrimidine catabolism: uracil → dihydrouracil; thymine → dihydrothymine
Clinical genetics: Often asymptomatic; neurological complications in severe cases (intellectual disability, seizures, abnormal MRI)
Critical pharmacogenomic significance: 5-fluorouracil (5-FU) is a substrate for DPD. Patients with DPD deficiency (even heterozygotes) have markedly reduced 5-FU metabolism → severe, life-threatening 5-FU toxicity (mucositis, myelosuppression, neurotoxicity)
DPD testing is now recommended before 5-FU-based chemotherapy

C. Pyrimidine-5'-Nucleotidase-1 (P5'N-1) Deficiency

Most frequent disorder of red cell nucleotide metabolism
P5'N-1 dephosphorylates pyrimidine nucleotides → nucleosides → diffuse out of RBCs
Deficiency → pyrimidine nucleotide accumulation → precipitation in RBCs → shortened RBC lifespan
Clinical: Nonspherocytic hemolytic anemia; prominent basophilic stippling (pathognomonic - the only RBC enzyme deficiency where morphology is diagnostic)
Inheritance: Autosomal recessive; gene NT5C3A on chromosome 7p14.3
Acquired form: Lead poisoning inhibits P5'N-1 → explains basophilic stippling in lead toxicity
Tietz Textbook of Laboratory Medicine, 7e, p. 1856

6. Summary Table: Purine & Pyrimidine Disorders

Disorder	Defective Enzyme	Key Feature	Clinical Presentation
Gout	PRPP synthetase (overactive) or renal handling	Uric acid crystals	Painful arthritis, tophi, nephrolithiasis
Lesch-Nyhan	HGPRT (complete)	X-linked recessive; PRPP excess	Self-mutilation, choreoathetosis, hyperuricemia
Kelley-Seegmiller	HGPRT (partial)	Partial HGPRT deficiency	Gout, no neurological features
ADA deficiency	Adenosine deaminase	dATP accumulation	SCID (T + B cell deficiency)
PNP deficiency	Purine nucleoside phosphorylase	dGTP accumulation	T-cell immunodeficiency, normal B cells
Von Gierke	Glucose-6-phosphatase	Excess PRPP	Secondary gout + hypoglycemia, lactic acidosis
Xanthinuria	Xanthine oxidase	Cannot make uric acid	Hypouricemia, xanthine stones
Orotic aciduria I	UMP synthase	Orotic acid excess	Megaloblastic anemia; responds to uridine
DPD deficiency	Dihydropyrimidine dehydrogenase	5-FU toxicity	Neurological; 5-FU pharmacotoxicity
P5'N-1 deficiency	Pyrimidine-5'-nucleotidase-1	Pyrimidine accumulation in RBCs	Hemolytic anemia + basophilic stippling

7. Pharmacological Targets in This Pathway

Drug	Target	Use
Allopurinol	Xanthine oxidase (competitive/irreversible via alloxanthine)	Gout, tumor lysis syndrome
Febuxostat	Xanthine oxidase (non-purine inhibitor)	Gout (fewer drug interactions)
Methotrexate	Dihydrofolate reductase	Blocks N10-formyl-FH4 → blocks both purine and thymidylate synthesis
5-Fluorouracil	Thymidylate synthase (via FdUMP)	Cancer; requires DPD for catabolism
Hydroxyurea	Ribonucleotide reductase	Cancer, sickle cell disease
6-Mercaptopurine / 6-TG	Multiple purine synthesis steps (via HGPRT conversion to nucleotides)	Leukemia
Probenecid	Renal urate transporter (URAT1)	Uricosuric in gout

Sources:

Basic Medical Biochemistry, 6e, Chapter 39 (pp. 1404-1415) - most comprehensive pathway coverage
Harper's Illustrated Biochemistry, 32e, Chapter 33 (pp. 354-358) - disorders table and catabolism
Bradley and Daroff's Neurology in Clinical Practice, Chapter 91 (p. 1950) - neurological manifestations
Tietz Textbook of Laboratory Medicine, 7e, Chapter on RBC nucleotide metabolism (pp. 1856-1860) - P5'N-1 deficiency

Disorders of purine metabolism

Reading File

Finding Sources

Reading File

Loading Image

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

I now have comprehensive, multi-textbook content with rich images. Let me compose the full answer.

Disorders of Purine Metabolism

Purine metabolism disorders arise from disruption of de novo synthesis, salvage pathways, or catabolic pathways. Because uric acid - the end product of human purine catabolism - has poor water solubility, most purine disorders manifest as hyperuricemia, crystal deposition, or immunodeficiency (when salvage enzymes in lymphocytes are impaired).

Quick Reference: Purine Catabolism Pathway

Purine catabolism: Adenosine → (adenosine deaminase) → Inosine; Guanosine → (purine nucleoside phosphorylase) → Hypoxanthine / Guanine → (xanthine oxidase) → Xanthine → (xanthine oxidase) → Uric acid

Purine nucleoside catabolism. Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) are critical enzymes - their deficiency causes immunodeficiency. Xanthine oxidase converts hypoxanthine/xanthine → uric acid; its inhibition is the target of allopurinol.

Purine Salvage Pathway - The Site of Most Disorders

Purine salvage pathway: Hypoxanthine + PRPP → IMP (via HGPRT); Guanine + PRPP → GMP (via HGPRT); Adenine + PRPP → AMP (via APRT)

Purine salvage enzymes. HGPRT salvages hypoxanthine and guanine. APRT salvages adenine. Deficiency of HGPRT causes Lesch-Nyhan syndrome. Note the block symbol at HGPRT.

1. Gout and Hyperuricemia

Pathophysiology

Normal serum urate solubility limit is ~6.8 mg/dL. When exceeded, monosodium urate (MSU) crystals precipitate preferentially in cooler peripheral tissues (first metatarsophalangeal joint = "podagra"). Only ~10% of individuals with hyperuricemia actually develop gout.

Causes of hyperuricemia:

Category	Mechanism	Examples
Overproduction	Increased purine synthesis/catabolism	PRPP synthetase overactivity, HGPRT deficiency, myeloproliferative disorders, tumor lysis
Underexcretion (~90% of cases)	Impaired renal urate handling	Idiopathic; thiazide diuretics; lead nephropathy; cyclosporine
Combined	Both	Von Gierke disease, Lesch-Nyhan syndrome

Specific enzyme defects causing overproduction:

PRPP synthetase gain-of-function mutations: Elevated Vmax, increased affinity for ribose 5-phosphate, or resistance to feedback inhibition by AMP/GMP - all drive excess PRPP → excess purine synthesis → excess uric acid
HGPRT partial deficiency (Kelley-Seegmiller syndrome): Cannot salvage hypoxanthine/guanine → PRPP accumulates → de novo purine overproduction

Inflammatory Mechanism (Gout Attack)

Pathogenesis of acute gouty arthritis: Hyperuricemia → urate crystal precipitation in joints → macrophage phagocytosis → inflammasome activation, IL-1 release, lysosome rupture → neutrophil recruitment → neutrophils phagocytose crystals → neutrophil lysis → release of lysosomal enzymes → tissue injury and inflammation (depicted as inflamed great toe)

Key steps: MSU crystals → NLRP3 inflammasome activation in macrophages → IL-1β release → massive neutrophil influx → neutrophils phagocytose crystals → lysosomal rupture → proteolytic enzyme release → tissue injury.

Morphology

Acute arthritis: Dense neutrophilic infiltrates; needle-shaped urate crystals in synovium and neutrophil cytoplasm
Polarized light microscopy: Crystals show negative birefringence (yellow when parallel, blue when perpendicular to polarizer axis)
Tophi: Chalky deposits of urate crystals surrounded by reactive fibroblasts, mononuclear cells, and giant cells; erode cartilage and bone
Gouty nephropathy: Urate crystal deposition in renal interstitium; can cause chronic kidney disease; acute uric acid nephropathy causes AKI (especially in tumor lysis syndrome)

Treatment

Drug	Mechanism	Use
Colchicine	Inhibits microtubule polymerization; blocks neutrophil migration and inflammasome activation	Acute attack + prophylaxis
NSAIDs (indomethacin)	COX inhibition	Acute attack
Corticosteroids	Broad anti-inflammatory	Acute attack (when NSAIDs/colchicine contraindicated)
Allopurinol	Xanthine oxidase inhibitor (structural analogue of hypoxanthine; oxidized to alloxanthine, which tightly inhibits the enzyme)	Chronic urate lowering
Febuxostat	Non-purine xanthine oxidase inhibitor	Chronic urate lowering; fewer drug interactions than allopurinol
Probenecid	Blocks URAT1 (renal urate reabsorption transporter)	Uricosuric; only when underexcretor
Rasburicase	Recombinant uricase; converts uric acid → allantoin (water-soluble)	Tumor lysis syndrome prophylaxis/treatment
Pegloticase	PEGylated uricase	Refractory chronic gout

- Robbins Pathologic Basis of Disease, pp. 1112-1114; Harper's Illustrated Biochemistry, 32e, p. 354

2. Lesch-Nyhan Syndrome

The prototypical purine salvage disorder.

Feature	Detail
Gene	HPRT1 (Xq26-27)
Inheritance	X-linked recessive (affects males; females are carriers)
Enzyme	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) - complete deficiency

Biochemical Mechanism

HGPRT salvages hypoxanthine → IMP and guanine → GMP. With complete deficiency:

Hypoxanthine and guanine cannot be salvaged → both are catabolized to uric acid (massive overproduction)
Intracellular PRPP accumulates (no longer consumed by salvage) → drives de novo purine overproduction further
IMP and GMP are depleted → loss of feedback inhibition of amidophosphoribosyltransferase (GPAT) → de novo synthesis runs unchecked

Mutations include deletions, frameshift mutations, base substitutions, and aberrant mRNA splicing.

Clinical Features

"The 3 H's":

Hyperuricemia - uric acid nephrolithiasis, gouty arthritis, tophi (can appear in first weeks of life as orange "uric acid sand" in diapers)
Hypotonia progressing to hypertonia, choreoathetosis, spasticity, dysarthria, hyperreflexia
Harm (self-mutilation) - pathognomonic compulsive self-injurious behavior: biting of lips, fingers, and buccal mucosa; paradoxically patients are distressed by their own behavior

Other features: cognitive impairment, megaloblastic anemia (from purine depletion in rapidly dividing cells).

Kelley-Seegmiller syndrome = partial HGPRT deficiency: severe gout ± mild neurological features, but no self-mutilation. As functional enzyme increases, severity decreases.

Treatment

Allopurinol controls hyperuricemia and prevents nephropathy/gout
No treatment reverses the neurological features - the most disabling aspect
Physical restraints are often used to prevent self-injury (paradoxically, many patients request them)
Symptomatic: baclofen, benzodiazepines for spasticity/dystonia

- Harper's 32e, p. 355-356; Lippincott Biochemistry 8e, pp. 834-835; Tietz Laboratory Medicine, 7e

3. Adenosine Deaminase (ADA) Deficiency → SCID

Biochemistry

ADA deficiency mechanism: DNA degradation → adenosine + deoxyadenosine; ADA normally converts these to inosine + deoxyinosine. In ADA deficiency, deoxyadenosine accumulates → T and B cell lymphotoxicity → SCID

ADA deficiency: deoxyadenosine accumulates and is phosphorylated to dATP in lymphocytes. dATP inhibits ribonucleotide reductase, blocking DNA synthesis and triggering apoptosis of lymphocyte progenitors.

Feature	Detail
Inheritance	Autosomal recessive
Frequency	~15-20% of all SCID cases; most common cause of autosomal recessive SCID
Enzyme	Adenosine deaminase: adenosine → inosine; deoxyadenosine → deoxyinosine

Mechanism

ADA deficiency → deoxyadenosine accumulates
Lymphocytes (especially T cells) lack efficient dephosphorylation enzymes → deoxyadenosine is phosphorylated to dATP
dATP directly inhibits ribonucleotide reductase → DNA precursor depletion → lymphocyte apoptosis
Both T cells and B cells are decimated (though T cells are more severely affected)
Extra-lymphoid effects: Bone dysplasia with abnormal costochondral junctions and metaphyses (50% of cases); neurologic defects; because ADA is a ubiquitous enzyme

Clinical Features

Severe Combined Immunodeficiency (SCID): Absent T cells, B cells, and NK cells
Onset in early infancy with recurrent, life-threatening infections (bacterial, viral, fungal, opportunistic)
Failure to thrive
Thymus is small and devoid of lymphocytes (vs. X-linked SCID where thymic lobules retain epithelial structure)
Without treatment, fatal within the first 1-2 years of life

Treatment

Hematopoietic stem cell transplantation (HSCT) - curative standard of care
PEG-ADA (pegylated bovine ADA): Enzyme replacement; modified ADA stays in extracellular fluid where it degrades toxic purines before they enter lymphocytes. PEGylation extends half-life (3-6 days) and reduces immunogenicity. Restores immunoprotection but does not fully correct T lymphopenia.
Gene therapy: ADA deficiency was one of the first diseases treated with gene therapy (1990). Current trials use safer lentiviral vectors with excellent outcomes. ADA-SCID gene therapy is now approved (Strimvelis in Europe).

- Robbins, p. 232; Harrison's 22e, p. 2842; Thompson & Thompson Genetics, p. 319-320

4. Purine Nucleoside Phosphorylase (PNP) Deficiency

Feature	Detail
Inheritance	Autosomal recessive
Enzyme	Purine nucleoside phosphorylase: inosine/guanosine → hypoxanthine/guanine + ribose 1-phosphate
Frequency	Very rare; <100 cases reported worldwide

Mechanism

PNP deficiency → accumulation of inosine, guanosine, deoxyinosine, and especially deoxyguanosine
dGTP accumulates specifically in T cells (T cells lack efficient dephosphorylation)
dGTP inhibits ribonucleotide reductase → T cell apoptosis
B cells have efficient pathways to dephosphorylate dGTP → B cells are relatively spared

Clinical Features

Selective profound T-cell deficiency with apparently normal B-cell numbers and function
Recurrent infections, particularly viral and opportunistic
Autoimmune manifestations (due to abnormal immune regulation without adequate T-cell suppression)
Severe neurologic impairments (intellectual disability, spastic diplegia, cerebellar ataxia) - important distinguishing feature from ADA deficiency
Hypouricemia (cannot produce uric acid from inosine/guanosine)

Contrast with ADA deficiency:

Feature	ADA Deficiency	PNP Deficiency
Cells affected	T + B + NK	Mainly T cells
Toxic metabolite	dATP	dGTP
Uric acid	Normal or elevated	Low (hypouricemia)
Neurologic features	Moderate	Prominent
Autoimmune features	Less common	Common

- Harper's 32e, p. 357; Harrison's 22e, p. 2842; Bradley & Daroff Neurology

5. Von Gierke Disease (Glycogen Storage Disease Type 1a) - Secondary Hyperuricemia

Feature	Detail
Primary defect	Glucose-6-phosphatase deficiency
Mechanism of hyperuricemia	Enhanced glycolysis with pentose phosphate pathway shunting → excess ribose 5-phosphate → excess PRPP → overproduction of purines
Compounding factor	Associated lactic acidosis competes with uric acid for renal tubular secretion → elevates renal threshold for urate → further raises serum uric acid
Clinical	Severe hypoglycemia, hepatomegaly, growth retardation + secondary gout

- Harper's 32e, p. 356

6. Xanthinuria (Xanthine Oxidase Deficiency)

Feature	Detail
Defect	Xanthine oxidase (genetic or acquired from severe liver disease)
Consequence	Cannot convert hypoxanthine/xanthine → uric acid
Lab findings	Hypouricemia; elevated urinary xanthine and hypoxanthine
Clinical	Often asymptomatic; severe cases → xanthine urolithiasis (xanthine stones; less soluble than uric acid at physiologic urinary pH)
Molybdenum cofactor deficiency	Combined deficiency of xanthine oxidase + sulfite oxidase (both require Mo cofactor); causes severe neurological disease in neonates

7. Adenine Phosphoribosyltransferase (APRT) Deficiency

Feature	Detail
Defect	APRT (salvages adenine → AMP)
Inheritance	Autosomal recessive
Consequence	Adenine cannot be salvaged → adenine is oxidized by xanthine oxidase to 2,8-dihydroxyadenine (2,8-DHA)
Clinical	2,8-DHA urolithiasis (radiolucent stones, often misidentified as uric acid stones); can cause acute and chronic kidney disease
Uric acid levels	Normal (uric acid pathway unaffected)
Diagnosis	Stone analysis; urine microscopy shows distinctive brown crystals; genetic testing
Treatment	Allopurinol (inhibits xanthine oxidase, blocking 2,8-DHA production) + low-purine diet

- Campbell-Walsh Urology

8. PRPP Synthetase Superactivity

Feature	Detail
Defect	Gain-of-function mutations in PRPP synthetase
Inheritance	X-linked
Mechanism	Elevated Vmax; increased affinity for ribose 5-phosphate; resistance to feedback inhibition by AMP/GMP → excess PRPP → overproduction of purines
Clinical	Early-onset severe gout, nephrolithiasis; some variants associated with sensorineural deafness and neurodevelopmental features

9. Comprehensive Summary Table

Disorder	Defective Enzyme	Pathway	Inheritance	Key Biochemical Finding	Cardinal Clinical Feature
Gout (primary)	PRPP synthetase (gain-of-function) / renal handling	Synthesis / excretion	X-linked / polygenic	Hyperuricemia	Painful arthritis, tophi, nephropathy
Lesch-Nyhan syndrome	HGPRT (complete)	Salvage	X-linked recessive	↑↑ Uric acid, ↑ PRPP	Self-mutilation, choreoathetosis, hyperuricemia
Kelley-Seegmiller	HGPRT (partial)	Salvage	X-linked recessive	↑ Uric acid	Gout only; no neurological features
ADA deficiency	Adenosine deaminase	Catabolism	Autosomal recessive	↑ dATP in lymphocytes	SCID (T + B + NK cell deficiency)
PNP deficiency	Purine nucleoside phosphorylase	Catabolism	Autosomal recessive	↑ dGTP; hypouricemia	T-cell SCID + neurological impairment
Von Gierke disease	Glucose-6-phosphatase	Secondary (glycogen storage)	Autosomal recessive	↑ PRPP, lactic acidosis	Hypoglycemia + secondary gout
Xanthinuria	Xanthine oxidase	Catabolism	Autosomal recessive	Hypouricemia, ↑ urinary xanthine	Xanthine urolithiasis
APRT deficiency	APRT	Salvage	Autosomal recessive	↑ 2,8-DHA in urine	2,8-DHA kidney stones; normal uric acid
PRPP synthetase superactivity	PRPP synthetase	Synthesis	X-linked	↑↑ PRPP, ↑ uric acid	Early severe gout ± deafness

10. Key Pharmacological Targets in Purine Disorders

Drug	Target	Clinical Use
Allopurinol	Xanthine oxidase (inhibited by alloxanthine)	Gout, Lesch-Nyhan, APRT deficiency, tumor lysis prophylaxis
Febuxostat	Xanthine oxidase (non-purine inhibitor)	Gout (fewer drug interactions)
Rasburicase / Pegloticase	Uricase (converts uric acid → allantoin)	Tumor lysis / refractory gout
Colchicine	Microtubule polymerization; NLRP3 inflammasome	Acute gout; prophylaxis
PEG-ADA	Exogenous ADA enzyme replacement	ADA-SCID
6-Mercaptopurine / Azathioprine	Converted by HGPRT to cytotoxic nucleotides	Leukemia; immunosuppression (note: requires HGPRT)
Methotrexate	Dihydrofolate reductase	Blocks N10-formyl-FH4 → impairs de novo purine synthesis

Sources:

Harper's Illustrated Biochemistry, 32e, Ch. 33, pp. 354-357 - disorders table, Lesch-Nyhan, Von Gierke, ADA/PNP
Lippincott Illustrated Reviews: Biochemistry, 8e, Ch. 22, pp. 834-835 - Lesch-Nyhan mechanism and salvage pathway diagram
Robbins & Cotran Pathologic Basis of Disease, Ch. 6 and Ch. 26, pp. 232, 1112-1114 - ADA/SCID pathology; gout morphology and inflammatory mechanism
Harrison's Principles of Internal Medicine, 22e, p. 2842 - ADA/PNP deficiency in SCID classification
Thompson & Thompson Genetics and Genomics in Medicine, 9e, pp. 319-320 - PEG-ADA and gene therapy for ADA-SCID
Basic Medical Biochemistry, 6e, Ch. 39, pp. 1404-1415 - comprehensive pathway overview

This is a shared conversation. Sign in to Orris to start your own chat.